NCT01336803View on ClinicalTrials.gov

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

October 31, 2023

Conditions
Bone CancerChondrosarcomaEwing's SarcomaOsteosarcomaRhabdomyosarcomaBone NecrosisBone SarcomaOsteomyelitis
Interventions
DRUG

Feraheme

5 mg/kg by intravenous (IV) administration

PROCEDURE

Magnetic Resonance Imaging (MRI) scan

Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Heike E Daldrup-Link

OTHER

NCT01336803 - Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | Biotech Hunter | Biotech Hunter